APA (7th ed.) Citation

PD, S., SL, W., C, P., N, L., J, T., LP, M., . . . F, S. (2021). Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic oncology, 163(2), 246. https://doi.org/10.1016/j.ygyno.2021.08.024

Chicago Style (17th ed.) Citation

PD, Shah, et al. "Combination ATR and PARP Inhibitor (CAPRI): A Phase 2 Study of Ceralasertib Plus Olaparib in Patients with Recurrent, Platinum-resistant Epithelial Ovarian Cancer." Gynecologic Oncology 163, no. 2 (2021): 246. https://doi.org/10.1016/j.ygyno.2021.08.024.

MLA (9th ed.) Citation

PD, Shah, et al. "Combination ATR and PARP Inhibitor (CAPRI): A Phase 2 Study of Ceralasertib Plus Olaparib in Patients with Recurrent, Platinum-resistant Epithelial Ovarian Cancer." Gynecologic Oncology, vol. 163, no. 2, 2021, p. 246, https://doi.org/10.1016/j.ygyno.2021.08.024.